Skip to main content
Premium Trial:

Request an Annual Quote

Yourgene Health Completes Acquisition of Elucigene Diagnostics

NEW YORK (GenomeWeb) – UK prenatal testing firm Yourgene Health said late last week that it has completed the acquisition of Delta Diagnostics, which trades under the name Elucigene Diagnostics.

Yourgene had said earlier this month that it was planning to acquire Elucigene for £9.2 million ($12 million) in cash and stock. Both companies are located in Manchester, UK.

Elucigene has been developing in vitro diagnostics for oncology and reproductive health, including tests for cystic fibrosis screening and prenatal fetal aneuploidy screening.

Yourgene said that Elucigene's product portfolio is complementary to its own. Following the acquisition, it plans to develop and launch additional next-generation sequencing and other molecular diagnostic products.

"The commercial, scientific, and financial opportunities created by the acquisition are hugely exciting and we look forward to combining our respective Manchester operations," said Yourgene CEO Lyn Rees in a statement.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.